Use of cancer‐specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors

Abstract excerpt

Detection of recurrent somatic rearrangements routinely allows monitoring of residual disease burden in leukemias, but is not used for most solid tumors. However, next-generation sequencing now allows rapid identification of patient-specific rearrangements in solid tumors. We mapped genomic rearrangements in three cancers and showed that PCR assays for rearrangements could detect a single copy of the tumor genome...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Genomics and Diagnostics
• Share to Genomic variations and chromosomal abnormalities
• Share to Pancreatic and Hepatic Oncology Research